glp-1 agonist in esrd Frontiers GLP-1 receptor agonists (GLP-1RAs): cardiovascular
Description
To TT, Oparaugo NC, Kheshvadjian AR, Nelson AM, Agak GW
Effects of glucagonlike peptide1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
Comparative Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists With Regard to 6-Month Glycaemic Control and Weight Outcomes in Patients With Type 2 Diabetes
Semaglutide shows slower but more sustainable resultsstudies show consistent reduction over several months, with long-term maintenance possible through ongoing treatment and support
Beyond metabolic disorders, preliminary studies suggest potential benefits in cardiovascular disease prevention, neurodegenerative disorders, and nonalcoholic steatohepatitis (NASH), though further validation is needed [48]
Further analysis revealed that the C622S TRPA1 channel was activated by JWU-A021 in a manner nearly identical to that of the WT (Fig
